Earnings call transcript: Penumbra's Q2 2025 performance shows strong growth

Penumbra Inc. (PEN) reported strong Q2 2025 results, with total revenue increasing 13.4% year-over-year to $339.5 million, primarily driven by a 22.6% rise in U.S. thrombectomy sales and the launch of new products like Ruby XL. The company raised its full-year 2025 revenue guidance to $1.355-$1.370 billion, representing 13-15% growth, and reiterated its target of achieving over 70% gross margins by late 2026. Strategic investments include a significant sales force expansion and specialization to capitalize on market opportunities, particularly in the growing U.S. thrombectomy market where it holds over 50% share in DVT, and the completion of enrollment for the STORM-PE trial, which could significantly impact pulmonary embolism treatment. Despite these positive financial and operational advancements, the stock saw a slight decline, reflecting a cautious market reaction amid ongoing FDA review for its Thunderbolt device and broader industry risks.

Analysis

Penumbra (PEN) reported robust Q2 2025 results, with total revenue increasing 13.4% year-over-year to $339.5 million, primarily driven by a 22.6% rise in U.S. thrombectomy sales. The company raised its full-year 2025 revenue guidance to $1.355-$1.370 billion, representing 13-15% growth, and targets over 70% gross margins by late 2026. Adjusted EBITDA reached $61.4 million (18.1% of revenue), supported by a strong, debt-free balance sheet of $424.6 million cash.

Strategic initiatives, including new product launches like Ruby XL, are bolstering growth and opening new market segments. Penumbra has significantly expanded and specialized its sales force to enhance focus on thrombectomy and embolization, contributing to market share gains in the rapidly expanding U.S. thrombectomy market, where it now holds over 50% in DVT. International growth is also expected to resume in H2 2025.

Key clinical advancements include the completed enrollment for the STORM-PE trial, potentially shifting PE treatment standards, and the launch of the STRIDE 2 study. The ongoing FDA review for the Thunderbolt neurovascular device remains a significant future catalyst, with management expressing strong confidence despite the thorough regulatory process. These developments underscore Penumbra's commitment to innovation.

Despite these positive financial and operational advancements, PEN's stock experienced a cautious market reaction, closing down 1.8%. The company acknowledges potential risks such as supply chain disruptions, market saturation, and regulatory hurdles, warranting continued vigilance. However, the overall sentiment remains optimistic, supported by strong company fundamentals and strategic execution.

Key Decisions for Investors

• Investors should consider Penumbra's strong revenue growth and market share gains in the expanding U.S. thrombectomy market, particularly with the strategic sales force specialization and new product contributions like Ruby XL.
• Monitor the upcoming STORM-PE trial results this fall, as positive data could significantly expand the addressable market for PE treatment, and track progress on the FDA review for the Thunderbolt device as a key neurovascular catalyst.
• Evaluate the company's robust financial health, including strong cash position and gross margin expansion targets, while remaining vigilant on potential industry-wide risks such as supply chain issues and regulatory challenges.